Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations

40

NEW YORK–(BUSINESS WIRE)–Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations…

 

http://www.businesswire.com/news/home/20190604006119/en/Prevail-Therapeutics-Announces-IND-Active-Phase-12/